Streetbeat News

Stock Prices

PTGX

Protagonist Therapeutics' stock is up following the announcement of a global license and collaboration agreement with Takeda for the development and commercialization of rusfertide.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 9:29 pm

CVGW

Calavo Growers (NASDAQ:CVGW) reported a Q4 2023 adjusted EPS of $(0.33), which missed the analyst consensus estimate of $0.19 by 273.68%. Quarterly sales were $241.20M, falling short of the $263.40M estimate by 8.43%, and representing a 0.97% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 9:29 pm

CARV

Carver Bancorp, Inc. has declined an offer from Dream Chasers to acquire a 35% stake in Carver's common equity. The decision to reject the proposal was made public, but the reasons behind the decision or the terms of the offer were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 9:27 pm

MET

MetLife, Inc. (MET) shares have declined following the release of the company's fourth-quarter financial results.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 9:26 pm

BHE

Benchmark Electronics (BHE) reported Q4 adjusted EPS of $0.58, surpassing the consensus estimate of $0.56. However, their quarterly sales of $691.35M fell short of the expected $707.50M, marking a 7.90% decrease from the previous year.

Portfolio Pulse from mahesh@benzinga.com

January 31, 2024 | 9:26 pm

CMPR

Cimpress (NASDAQ:CMPR) reported Q2 earnings with an EPS of $2.14, surpassing the estimate of $1.24 by 72.58%. Revenue increased by $76.16 million compared to the same period last year. The previous quarter's EPS beat resulted in a 1.08% share price increase the following day.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 9:25 pm

DGII

Digi Intl (NASDAQ:DGII) reported Q1 earnings with an EPS of $0.48, beating estimates by 9.09% but with a revenue decline of $3.22 million from the previous year. The company has a history of surpassing EPS estimates, which in the last quarter led to a 0.86% stock price increase the following day.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 9:25 pm

MXL

MaxLinear (NASDAQ:MXL) reported Q4 earnings with EPS of $0.01, meeting estimates, but revenue declined by $165.23 million year-over-year. Last quarter's EPS miss led to a 21.96% share price drop the following day. Historical earnings data shows fluctuating performance over the past year.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 9:25 pm

ARAY

Accuray (NASDAQ:ARAY) reported Q2 earnings with an EPS of $-0.1, missing estimates by 100% compared to the expected $-0.05. Revenue decreased by $7.52 million from the same period last year. In the previous quarter, Accuray beat EPS estimates but the share price fell by 2.56% the following day.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 9:25 pm

OLMA

Olema Pharmaceuticals has filed a prospectus related to the resale of up to 13.2 million shares of common stock held by selling stockholders. This filing indicates that current shareholders may be looking to sell a significant portion of their holdings.

Portfolio Pulse from Charles Gross

January 31, 2024 | 9:24 pm